作者: S L Topalian , D Solomon , F P Avis , A E Chang , D L Freerksen
关键词:
摘要: Clinical investigations using the adoptive transfer of lymphokine-activated killer (LAK) cells and recombinant interleukin-2 (rIL-2) to treat patients with advanced cancer have yielded …